AstraZeneca jettisons European heart drug rights for $210m
July 24, 2018Manufacturing and Production, Sales and Marketing AstraZeneca, Atacand, Cheplapharm, blood pressure, heart failure, pharma
AstraZeneca has announced its intention to hand over the European commercial rights to its heart failure and blood pressure treatment …
First new treatment for reccurent malaria approved in over 60 years
July 23, 2018Manufacturing and Production FDA, GSK, approval, malaria, p.vivax
The FDA has approved GSK’s Krintafel for the treatment of a recurring form of malaria in patients aged 16 and …
The mission against antimicrobial resistance
July 23, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing antibiotic resistance, antimicrobial resistance, feature, pharma
Two headlines have highlighted the ‘here and now’ of the threat of rising antimicrobial resistance (AMR), writes Dr Peter Jackson.A …
FDA approves Agios’ oral leukaemia treatment Tibsovo
July 23, 2018Sales and Marketing FDA, agios, approval, pharmaceuticals, tibsovo
The oral leukaemia treatment Tibsovo (ivosidenib) produced by Massachusetts-based Agios Pharmaceuticals has been approved for treatment of adult patients with …
US court overturns Allergan’s controversial attempts to avoid Restasis patent review
July 23, 2018Sales and Marketing Allergan, Mylan, Restasis, US, dry eye, pharma
The US Court of Appeals for the Federal Circuit has seen fit to authorise a US Patent and Trademark Office …
Roche join Pfizer and others in price freeze while critics pose questions
July 23, 2018Sales and Marketing Donald Trump, Roche, generics, price freezes
Swiss multinational Roche has joined Pfizer and others in halting price hikes. However critics have condemned the move as observers …
FDA approves Pfizer biosimilar version of Amgen’s Neupogen
July 23, 2018Sales and Marketing Amgen, FDA, Neupogen, Nivestym, Pfizer, pharma
The FDA has announced its decision to approve Pfizer’s Nivestym, the firm’s biosimilar version of Amgen’s Neupogen (filgrastim), for use …
Chinese premier slams drug maker after vaccine scandal
July 23, 2018Sales and Marketing CCP, China, biotech, scandal, vaccines
Chinese Premier Li Keqiang has spoken out against drug maker Changsheng Biotechnology after the Chinese firm was found to have …
Top Ten most popular articles on Pharmafile.com this week
July 20, 2018Medical Communications GSK, ICR, J&J, JJ, Novartis, Trump, brexit, top 10
As Brexit negotions have hit a stalemate this week, the United Kingdom’s exit from the European Union has hit the …
Scottish borders-based Ryboquinn acquires viral delivery comany Nanogenics
July 20, 2018Medical Communications M&A, MA, Scotland, acquisitions, gene therapy, nanogenics, ryboquinn
The Scottish biotech company Ryboquinn has acquired English partner Nanogenics Solutions in a deal worth £4.45 million. The Selkirk-based firm …
FDA explores import strategy in effort to reduce price of drugs
July 20, 2018Medical Communications Drug pricing, Trump, borders, import, the donald
The FDA has been directed to explore ways in which medicines could be safely imported from other countries “in the …
Merck joins Pizer and Novartis in reducing drug prices
July 20, 2018Medical Communications Merck, Novartis, Pfizer, Trump, Twitter, price hikes
Merck & Co. have joined Pfizer and Novartis in halting price increases on medicines in the United States. The American …
Donald Trump thanks Novartis for halting price hikes
July 20, 2018Medical Communications Novartis, Pfizer, Trump, Twitter, price hikes
Donald Trump has thanked Swiss multinational Novartis for halting price hikes on prescription drugs in the United States. The US …
Novartis buys eczema drug in €95m deal
July 19, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, deal, eczema, experimental, patent
Novartis has agreed to buy the rights for a novel antibody MOR106 from the Belgo-Dutch pharmaceutical research company Galapagos and …
PhRMA take on PBM’s in response to Trump drug price plan
July 19, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
In response to Donald Trump’s plan to lower drug prices in the US, the Pharmaceutical Research and Manufacturers of America …
MPs vote to stay in EMA after Brexit
July 19, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, UK, brexit, parliament, vote
British MPs have voted for the UK’s continued participation in the regulatory network operated by the European Medicines Agency (EMA) …
Bill Gates commits $30m towards Alzheimer’s diagnostic test
July 19, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, Bill Gates, billionaire, diagnosis
Microsoft business magnate Bill Gates has joined a coalition of philanthropists in committing more than $30 million towards the development …
Janssen’s Symtuza scores approval with the FDA in HIV-1
July 18, 2018Sales and Marketing HIV, Janssen, Symtuza, pharma
Janssen has announced that Symtuza (D/C/F/TAF) has received approval from the FDA in the treatment of human immunodeficiency virus type …
AstraZeneca increases drug stockpile in preparation for no-deal Brexit
July 18, 2018Research and Development AstraZeneca, brexit, no-deal, pharma, stockpiling
The Anglo-Swedish drug giant AstraZeneca is set to increase its stockpile of drugs in both the United Kingdom and the …
Novartis follows Pfizer’s lead, pledges no price hikes in 2018
July 18, 2018Research and Development, Sales and Marketing Novartis, Pfizer, President trump, Trump, US, pharma
Following US pharma giant Pfizer’s clash with President Donald Trump after it was called out on Twitter for hiking the …
Latest content
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical
Claris reports visual acuity gains with experimental LSCD treatment
